How Teva Turned Olanzapine.com Into a High-Visibility Search Asset
Teva Pharmaceuticals acquired the exact-match Olanzapine.com domain in November 2024 and began developing the site in 2025.
Within a relatively short period, the domain developed into a significant organic-search property around a medicine directly represented in Teva’s generics business.
The supplied performance data now shows 400K+ search impressions, 200+ ranking keywords and 20+ top-three Google positions.
From acquisition to significant search visibility in under two years
The exact-match generic medicine domain moves into the ownership of a major generic-drug manufacturer.
Teva begins turning the previously undeveloped domain into an active web property with content centered on olanzapine.
The site reaches hundreds of thousands of impressions, 200+ ranking keywords and dozens of top-three search positions.
Teva: a major business in generic medicines
Teva Pharmaceuticals has a substantial presence in the generics industry. In the United States, Teva describes itself as a leading provider of generic drugs.
Its U.S. portfolio currently includes approximately 500 medicines, covering all major therapeutic categories.
That context makes Olanzapine.com particularly relevant. It is the exact generic name of a medicine represented within Teva’s own product portfolio.
Teva acquired the domain in November 2024, then began developing the site in 2025. The speed with which meaningful organic visibility followed makes the example especially notable.
Why Olanzapine.com is directly relevant to Teva
Olanzapine
An atypical antipsychotic medicine and a generic name directly represented in Teva’s U.S. pharmaceutical portfolio.
Teva markets Olanzapine Orally Disintegrating Tablets, USP in the United States.
Teva’s current product catalog places the medicine in the Antipsychotics, Atypical Antipsychotics therapeutic category and identifies Zyprexa® Zydis® as the brand equivalent.
Teva lists the product in four strengths: 5 mg, 10 mg, 15 mg and 20 mg.
Olanzapine continues to be relevant to Teva’s pharmaceutical business
Teva’s connection with the olanzapine molecule extends beyond its currently marketed generic tablets.
In 2026, Teva’s investigational extended-release olanzapine program continued to progress, reinforcing the molecule’s ongoing relevance to the company.
That makes the acquisition and development of Olanzapine.com especially interesting as a digital case study.
Teva lists olanzapine orally disintegrating tablets in multiple strengths in its U.S. portfolio.
The exact-match .com provides an intuitive digital identity around the generic medicine name.
The site began development in 2025 and built substantial visibility during the following year.
One medicine. One definitive .com.
Generic medicine names are searched by patients, healthcare professionals, pharmacies, researchers and other stakeholders.
Pharmaceutical companies commonly accommodate those products within large corporate websites and extensive product catalogs.
An exact-match domain offers another option.
Olanzapine.com immediately communicates what the digital property is about.
In Teva’s case, the domain also aligns naturally with the company’s generics portfolio and with a medicine the company actually supplies.
Teva + Olanzapine.com
- Major generic pharmaceutical manufacturer
- Olanzapine represented in Teva’s U.S. portfolio
- Domain acquired in November 2024
- Site development began in 2025
- 400K+ impressions by 2026
From pharmaceutical domain to active Teva web property
Teva acquired Olanzapine.com in November 2024.
Development began in 2025, turning the previously undeveloped domain into an active property focused on its pharmaceutical subject.
That relatively short development window is important when looking at the site’s subsequent search performance.
- Clear and memorable pharmaceutical identity
- Direct semantic connection to the medicine
- Independent of any single product brand
- Suitable for a focused medicine-specific destination
- Unique digital asset — only one Olanzapine.com exists
An exact-match domain does not automatically create Google rankings. Content quality, technical implementation, authority, competition and many other signals influence organic search performance.
The significance of the Teva example is that a highly relevant pharmaceutical domain was acquired, developed in 2025, and then built substantial visibility within a relatively short period.
From development in 2025 to hundreds of thousands of impressions
Search visibility accelerated quickly as the site matured
The supplied data shows Olanzapine.com progressing from negligible visibility in 2025 to approximately 400,000+ impressions.
At points during 2026, visibility approached approximately 450,000–500,000 impressions.
Teva only acquired the domain in November 2024, and development of the website began in 2025.
Olanzapine.com quickly built a broader organic search footprint
The site’s progress is not limited to one isolated keyword.
The supplied ranking data shows Olanzapine.com appearing across an expanding set of organic search queries, with approximately 200+ keywords within Google’s top 50 by September 2026.
That growth took place after development began in 2025, giving the site a meaningful organic footprint in roughly its first full year of active development.
Olanzapine.com began competing near the top of Google
Dozens of queries reached Google’s top three positions
During 2026, the number of keywords ranking in positions 1–3 increased sharply.
The supplied data shows a peak of approximately 32 top-three rankings, with the domain remaining around the 20+ top-three level toward the end of the period shown.
Given that Teva acquired the domain in late 2024 and only began developing the site in 2025, that progression is particularly significant.
The value is in the alignment between company, medicine and domain
There is no single factor responsible for organic rankings, and an exact-match domain is not a replacement for quality content or strong website execution.
The strategic value is the alignment.
Teva is a major generic pharmaceutical company. Olanzapine is a medicine within its portfolio. And Olanzapine.com is the exact digital address corresponding to that generic medicine name.
That combination creates an intuitive digital relationship between the manufacturer, the pharmaceutical subject and the website address.
In less than two years, an undeveloped domain became a significant Teva digital asset
The important part of the case study is not simply that Teva purchased Olanzapine.com.
It is the speed of what happened afterward.
Teva acquired the domain in November 2024, began developing it in 2025, and by 2026 the property had built substantial organic visibility.
That is the difference between viewing a premium pharmaceutical domain as a speculative asset and viewing it as digital infrastructure for a pharmaceutical business.
20+ top-three positions*
Olanzapine.com is one example from a much larger pharmaceutical domain portfolio
DigitalGenerics specializes in premium .com domains connected to generic medicines.
The portfolio contains more than 240 premium domain names and was built over decades, with domains dating back to 1998.
For pharmaceutical manufacturers and healthcare businesses, these domains offer the opportunity to acquire a direct .com associated with a relevant medicine.
What other pharmaceutical companies can learn from Teva’s example
Pharmaceutical manufacturers frequently manage extensive portfolios of generic medicines.
Teva’s experience with Olanzapine.com shows what can happen when a relevant exact-match domain is acquired and actively developed rather than simply held.
The speed of development is especially instructive: acquisition in November 2024, site development beginning in 2025, and significant organic visibility by 2026.
Possible uses for other pharmaceutical companies include:
Medicine information hub
Create a dedicated digital destination centered on the generic medicine.
Product information
Complement a wider corporate product catalog with a focused medicine-specific property.
Healthcare-professional resources
Support professional information subject to applicable pharmaceutical and regulatory requirements.
Educational content
Develop useful content around a highly relevant pharmaceutical subject.
International strategy
Use a globally recognized .com within a broader international digital presence.
Strategic ownership
Secure a unique digital asset before it is acquired by another organization.
Could one of your medicines become the next case study?
Search our portfolio of 240+ premium generic-drug domain names and see whether the exact-match .com for one of your medicines is currently available.